Meeting
2020 Genitourinary Cancers Symposium
The effect of treatment sequence on overall survival for men with metastatic castration-resistant prostate cancer: A multicenter retrospective study.
Authors
Shingo Hatakeyama
Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Shingo Hatakeyama , Kazutaka Okita , Hayato Yamamoto , Takahiro Yoneyama , Yasuhiro Hashimoto , Chikara Ohyama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 238)
Abstract #
238
Poster Bd #
B16
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.
First Author: Celestia S. Higano
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
First Author: Emily Nash Smyth
Poster
2023 ASCO Genitourinary Cancers Symposium
Characteristics of long-term responder (LTR) patients (pts) treated with androgen-receptor signaling inhibitors (ARSI) as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC): Real-world evidence from four high-volume institutions.
First Author: Orazio Caffo
Poster
2017 Genitourinary Cancers Symposium
Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.
First Author: William K. Oh